Vancouver, British Columbia, May 20, 2021 — Genix Pharmaceuticals Corporation (TSX-V: GENX) (“GENIX” or the “Company”) is pleased to announce that shareholders have voted in favor of all items of business brought before them at the Company’s Annual General Meeting of Shareholders (the “AGM”) held in Vancouver, British Columbia on Wednesday May 21, 2021 (see www.sedar.com for results).
Shareholders approved the number of directors at six, the appointment of Harbourside CPA as the Company’s independent auditor, and the annual confirmation of the Company’s 10% rolling Stock Option Plan.
The shareholders re-elected Sina Pirooz, Darryl Yea, Paul Chow, Jamie Lewin, and Kevin Bottomley to the Company’s Board of Directors. In addition, Mahmoud Aziz has been elected to the Company’s Board of Directors and appointed as its President.
Genix Pharmaceuticals Corporation is a highly innovative, Canadian life-sciences company focused on the acquisition, research, development, manufacturing, sales and distribution of innovative, novel and generic prescription and OTC pharmaceuticals for the ophthalmological and other attractive markets and to satisfy unmet needs. Our mission is to provide Canadian’s access to affordable, highest quality, evidence-based, novel and generic prescription drugs and OTC medicines and nutraceutical products to improve their health and quality of life. All Genix products are developed and supported by evidence-based science and clinical studies and manufactured under the strictest Good Manufacturing Practices (GMP) protocols.
CEO, Director Genix Pharmaceuticals Corporation
For more information regarding GENIX, please contact:
Kevin Bottomley, Director